Physician profile
Lexi Lynn Mickey
NPI 1902383573
$9,806.31
in general payments reported to CMS, 2019-2025
28 companies · $3,978 in 2025
The $3,978 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,301 · 2022: $2,587 · 2023: $703 · 2024: $237 · 2025: $3,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,382 · Travel and Lodging: $476 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,381.61 |
| Travel and Lodging | $476.42 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,248.94 | 2021-2025 | |
| Amgen INC. | $1,916.75 | 2021-2025 | Otezla, Evenity, Krystexxa |
| Ucb, INC. | $957.63 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $737.58 | 2021-2025 | Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $561.39 | 2025 | |
| Pfizer INC. | $486.88 | 2021-2025 | |
| Lilly USA, LLC | $443.48 | 2021-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $405.24 | 2021-2025 | |
| Radius Health, INC. | $401.18 | 2022-2025 | Tymlos |
| Glaxosmithkline, LLC. | $292.52 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $247.12 | 2022-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $222.55 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $156.27 | 2021-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $150.98 | 2022-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $114.77 | 2021-2025 | Lupkynis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $82.89 | 2021-2022 | |
| Genzyme Corporation | $71.84 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $54.76 | 2022-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $46.01 | 2022-2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $40.88 | 2021-2025 | Actemra |
| Fresenius Kabi USA, LLC | $27.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.91 | 2021 | |
| Celltrion USA INC. | $25.56 | 2024 | Vegzelma |
| Boston Scientific Corporation | $20.61 | 2025 | Wavewriter Alpha Prime 16 |
| Organon LLC | $17.65 | 2025 | Nexplanon |
| Abbott Laboratories | $16.92 | 2025 | Proclaim |
| Ferring Pharmaceuticals INC. | $16.60 | 2021 | |
| Almatica Pharma LLC | $16.23 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lexi Mickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.